Skip to content
MedsAcross

Molecule

Penicillin g benzathine

Penicillin-class Antibacterial
Available on requestCold chain
Presentations
1
Brands
1
Manufacturers
1
Available from stock
0

Penicillin g benzathine is a penicillin-class antibacterial indicated in the treatment of infections due to penicillin-G-sensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. MedsAcross supplies Penicillin g benzathine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Key facts

Pharmacological class
Penicillin-class Antibacterial
US FDA first approval
22 November 1951
EU status
Not recorded
Orphan designation
Not recorded
WHO essential medicine
Not recorded
India (CDSCO)
Not yet confirmed against CDSCO approval lists
Routes
Intramuscular
Dosage forms
Injectable suspension
Identifiers
UNII RIT82F58GKRxCUI 7982CAS 41372-02-5Q27288139

Clinical information

From the regulator-approved product information. Each section names its source.

Uses

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin L-A and other antibacterial drugs, Bicillin L-A should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Intramuscular penicillin G benzathine is indicated in the treatment of infections due to penicillin-G-sensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response.

Source: US FDA prescribing information

How it works

Penicillin G exerts a bactericidal action against penicillin-susceptible microorganisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell-wall peptidoglycan, rendering the cell wall osmotically unstable.

Source: US FDA prescribing information

Dosing overview

Streptococcal (Group A) Upper Respiratory Infections (for example, pharyngitis) Adults—a single injection of 1,200,000 units, older pediatric patients—a single injection of 900,000 units, infants and pediatric patients under 60 lbs.—300,000 to 600,000 units. Syphilis Primary, secondary, and latent—2,400,000 units (1 dose). Late (tertiary and neurosyphilis)—2,400,000 units at 7-day intervals for three doses. Congenital—under 2 years of age: 50,000 units/kg/body weight, ages 2 to 12 years: adjust dosage based on adult dosage schedule. Yaws, Bejel, and Pinta —1,200,000 units (1 injection). Prophylaxis —for rheumatic fever and glomerulonephritis. Following an acute attack, penicillin G benzathine (parenteral) may be given in doses of 1,200,000 units once a month or 600,000 units every 2 weeks. METHOD OF ADMINISTRATION BICILLIN L-A IS INTENDED FOR INTRAMUSCULAR INJECTION ONLY.

Source: US FDA prescribing information

Contraindications

A history of a previous hypersensitivity reaction to any of the penicillins is a contraindication.

Source: US FDA prescribing information

Warnings and precautions

Boxed warning: Prior to administration of this drug, carefully read the WARNINGS, ADVERSE REACTIONS, and DOSAGE AND ADMINISTRATION sections of the labeling. WARNING NOT FOR INTRAVENOUS USE. DO NOT INJECT INTRAVENOUSLY OR ADMIX WITH OTHER INTRAVENOUS SOLUTIONS. THERE HAVE BEEN REPORTS OF INADVERTENT INTRAVENOUS ADMINISTRATION OF PENICILLIN G BENZATHINE WHICH HAS BEEN ASSOCIATED WITH CARDIORESPIRATORY ARREST AND DEATH. Boxed warning: Prior to administration of this drug, carefully read the WARNINGS, ADVERSE REACTIONS, and DOSAGE AND ADMINISTRATION sections of the labeling. Penicillin G benzathine should only be prescribed for the indications listed in this insert. Anaphylaxis SERIOUS AND OCCASIONALLY FATAL HYPERSENSITIVITY (ANAPHYLACTIC) REACTIONS HAVE BEEN REPORTED IN PATIENTS ON PENICILLIN THERAPY.

Source: US FDA prescribing information

Side effects

As with other penicillins, untoward reactions of the sensitivity phenomena are likely to occur, particularly in individuals who have previously demonstrated hypersensitivity to penicillins or in those with a history of allergy, asthma, hay fever, or urticaria. As with other treatments for syphilis, the Jarisch-Herxheimer reaction has been reported. The following adverse reactions have been reported with Bicillin L-A during post-marketing experience: Skin and Appendages: Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS). Immune System Disorders: Acute myocardial ischemia with or without myocardial infarction occurring as part of an allergic reaction.

Source: US FDA prescribing information

Interactions

Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin, and concurrent use of these drugs should be avoided. Concurrent administration of penicillin and probenecid increases and prolongs serum penicillin levels by decreasing the apparent volume of distribution and slowing the rate of excretion by competitively inhibiting renal tubular secretion of penicillin.

Source: US FDA prescribing information

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

All presentations

1 presentations of Penicillin g benzathine, sorted by availability.

MedicineManufacturerRegisterAvailability
Bicillin L-a 1200000 IU/2 mL injectable suspensionIntramuscular Cold chainPfizer LaboratoriesUS FDAAvailable on request

Brands by market

1 brand names across 1 markets.

Brand names by country

United States

Manufacturers

Regulatory status

Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.

RegisterStatusSource
US FDAFirst approved 22 November 1951Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Conditions

Conditions linked to Penicillin g benzathine in public data. This is not a list of approved uses, see the clinical information.

Questions and answers

Is Penicillin g benzathine available for export from India?

Yes, on request. MedsAcross lists 1 presentations of Penicillin g benzathine and sources them for licensed hospitals, importers and physicians against valid import documents.

What brand names does Penicillin g benzathine have?

The catalogue lists 1 brand names for Penicillin g benzathine, including Bicillin L-a.

Is Penicillin g benzathine approved by the US FDA?

Yes. The US FDA first approved Penicillin g benzathine on 22 November 1951, according to Drugs@FDA.

Does Penicillin g benzathine need cold chain shipping?

At least one listed presentation of Penicillin g benzathine must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.

References

  1. BICILLIN L-A prescribing information (Pfizer Laboratories). U.S. National Library of Medicine, DailyMed. Retrieved 21 July 2026

Request Penicillin g benzathine for export supply

Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.